Hepatitis Monthly

Published by: Kowsar
Uncorrected Proof scheduled for 18 (7)

Short-term Atorvastatin Administration and Efficacy of Hepatitis B Vaccination; a Randomized, Double-blind, Placebo-Controlled Clinical Trial

Nematollah Jonaidi Jafari 1 , Abbas Hosseinpour Azari 1 , Masood Beykpoor 1 , * , Morteza Izadi 1 , Eisa Salehi 2 , Hassan Nikoueinejad 3 , Mostafa Hosseini 4 , Mahdi Safiabadi 5 and Seyed Moayed Alavian 6
Authors Information
1 Health Research Center, Baqiyatallah University of Medical Sciences, Tehran, IR Iran
2 Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, IR Iran
3 Nephrology and Urology Research Center, Baqiyatallah University of Medical Sciences, Tehran, IR Iran
4 Department of Epidemiology and Biostatistics, School of Public Health and Institute of Public Health Research, Tehran University of Medical Sciences, Tehran, IR Iran
5 Student Research Committee, Baqiyatallah University of Medical Sciences, Tehran, IR Iran
6 Baqiyatallah Research Center for Gastroenterology and Liver Disease, Baqyiatallah University of Medical Sciences, Tehran, IR Iran
Article information
  • Hepatitis Monthly: , In Press (In Press); e14562
  • Published Online: June 9, 2018
  • Article Type: Research Article
  • Received: June 6, 2017
  • Revised: December 9, 2017
  • Accepted: December 16, 2017
  • DOI: 10.5812/hepatmon.14562

To Cite: Jonaidi Jafari N, Hosseinpour Azari A, Beykpoor M, Izadi M, Salehi E, et al. Short-term Atorvastatin Administration and Efficacy of Hepatitis B Vaccination; a Randomized, Double-blind, Placebo-Controlled Clinical Trial, Hepat Mon. Online ahead of Print ;In Press(In Press):e14562. doi: 10.5812/hepatmon.14562.

Abstract
Copyright © 2018, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Methods
3. Results
4. Discussion
Acknowledgements
Footnotes
References
  • 1. Wang T. Model of life expectancy of chronic hepatitis B carriers in an endemic region. J Epidemiol. 2009;19(6):311-8. [PubMed: 19801886]. [PubMed Central: PMC3924100].
  • 2. Trepo C, Chan HL, Lok A. Hepatitis B virus infection. Lancet. 2014;384(9959):2053-63.
  • 3. Bertino JJ, Tirrell P, Greenberg RN, Keyserling HL, Poland GA, Gump D, et al. A comparative trial of standard or high-dose S subunit recombinant hepatitis B vaccine versus a vaccine containing S subunit, pre-S1, and pre-S2 particles for revaccination of healthy adult nonresponders. J Infect Dis. 1997;175(3):678-81. [PubMed: 9041342].
  • 4. Roome AJ, Walsh SJ, Cartter ML, Hadler JL. Hepatitis B vaccine responsiveness in Connecticut public safety personnel. JAMA. 1993;270(24):2931-4. [PubMed: 8254852].
  • 5. Hollinger FB. Factors influencing the immune response to hepatitis B vaccine, booster dose guidelines, and vaccine protocol recommendations. Am J Med. 1989;87(3):S36-40.
  • 6. Filippelli M, Lionetti E, Gennaro A, Lanzafame A, Arrigo T, Salpietro C, et al. Hepatitis B vaccine by intradermal route in non responder patients: an update. World J Gastroenterol. 2014;20(30):10383-94. doi: 10.3748/wjg.v20.i30.10383. [PubMed: 25132754]. [PubMed Central: PMC4130845].
  • 7. Zaffina S, Marcellini V, Santoro AP, Scarsella M, Camisa V, Vinci MR, et al. Repeated vaccinations do not improve specific immune defenses against Hepatitis B in non-responder health care workers. Vaccine. 2014;32(51):6902-10. doi: 10.1016/j.vaccine.2014.10.066. [PubMed: 25444815].
  • 8. Shouval D, Roggendorf H, Roggendorf M. Enhanced immune response to hepatitis B vaccination through immunization with a Pre-S1/Pre-S2/S vaccine. Med Microbiol Immunol. 2015;204(1):57-68. doi: 10.1007/s00430-014-0374-x. [PubMed: 25557605]. [PubMed Central: PMC4305084].
  • 9. Wong B, Lumma WC, Smith AM, Sisko JT, Wright SD, Cai TQ. Statins suppress THP-1 cell migration and secretion of matrix metalloproteinase 9 by inhibiting geranylgeranylation. J Leukoc Biol. 2001;69(6):959-62. [PubMed: 11404382].
  • 10. Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med. 2000;6(12):1399-402. doi: 10.1038/82219. [PubMed: 11100127].
  • 11. Youssef S, Stuve O, Patarroyo JC, Ruiz PJ, Radosevich JL, Hur EM, et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature. 2002;420(6911):78-84. doi: 10.1038/nature01158. [PubMed: 12422218].
  • 12. Lee PY, Scumpia PO, Byars JA, Kelly KM, Zhuang H, Shuster JS, et al. Short-term atorvastatin treatment enhances specific antibody production following tetanus toxoid vaccination in healthy volunteers. Vaccine. 2006;24(19):4035-40. doi: 10.1016/j.vaccine.2005.12.042. [PubMed: 16464519].
  • 13. Cohen J. Statistical power analysis for the behavioral sciences (revised ed). New York: Academic Press; 1977.
  • 14. Packard RR, Schlegel S, Senouf D, Burger F, Sigaud P, Perneger T, et al. Atorvastatin treatment and vaccination efficacy. J Clin Pharmacol. 2007;47(8):1022-7. doi: 10.1177/0091270007302169. [PubMed: 17548534].
  • 15. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA. 1999;282(24):2340-6. [PubMed: 10612322].
  • 16. Cheung BM, Lauder IJ, Lau CP, Kumana CR. Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. Br J Clin Pharmacol. 2004;57(5):640-51. doi: 10.1111/j.1365-2125.2003.02060.x. [PubMed: 15089818]. [PubMed Central: PMC1884492].
  • 17. Hakamada-Taguchi R, Uehara Y, Kuribayashi K, Numabe A, Saito K, Negoro H, et al. Inhibition of hydroxymethylglutaryl-coenzyme a reductase reduces Th1 development and promotes Th2 development. Circ Res. 2003;93(10):948-56. doi: 10.1161/01.RES.0000101298.76864.14. [PubMed: 14563711].
  • 18. Aktas O, Waiczies S, Smorodchenko A, Dorr J, Seeger B, Prozorovski T, et al. Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin. J Exp Med. 2003;197(6):725-33. doi: 10.1084/jem.20021425. [PubMed: 12629065]. [PubMed Central: PMC2193848].
  • 19. Weitz-Schmidt G. Statins as anti-inflammatory agents. Trend Pharmacol Sci. 2002;23(10):482-7.
  • 20. Ferreira GA, Navarro TP, Telles RW, Andrade LE, Sato EI. Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: an 8 weeks controlled trial. Rheumatology (Oxford). 2007;46(10):1560-5. doi: 10.1093/rheumatology/kem186. [PubMed: 17693444].
  • 21. Charles-Schoeman C, Khanna D, Furst DE, McMahon M, Reddy ST, Fogelman AM, et al. Effects of high-dose atorvastatin on antiinflammatory properties of high density lipoprotein in patients with rheumatoid arthritis: a pilot study. J Rheumatol. 2007;34(7):1459-64. [PubMed: 17552046].
  • 22. El-Barbary AM, Hussein MS, Rageh EM, Hamouda HE, Wagih AA, Ismail RG. Effect of atorvastatin on inflammation and modification of vascular risk factors in rheumatoid arthritis. J Rheumatol. 2011;38(2):229-35. doi: 10.3899/jrheum.100582. [PubMed: 21041278].
  • 23. McInnes IB, Kim HY, Lee SH, Mandel D, Song YW, Connell CA, et al. Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study. Ann Rheum Dis. 2014;73(1):124-31. doi: 10.1136/annrheumdis-2012-202442. [PubMed: 23482473].
  • 24. Omer SB, Phadke VK, Bednarczyk RA, Chamberlain AT, Brosseau JL, Orenstein WA. Impact of Statins on Influenza Vaccine Effectiveness Against Medically Attended Acute Respiratory Illness. J Infect Dis. 2016;213(8):1216-23. doi: 10.1093/infdis/jiv457. [PubMed: 26516141]. [PubMed Central: PMC4799662].
  • 25. Weber MS, Prod'homme T, Youssef S, Dunn SE, Steinman L, Zamvil SS. Neither T-helper type 2 nor Foxp3+ regulatory T cells are necessary for therapeutic benefit of atorvastatin in treatment of central nervous system autoimmunity. J Neuroinflammation. 2014;11:29. doi: 10.1186/1742-2094-11-29. [PubMed: 24498870]. [PubMed Central: PMC3922392].
  • 26. Li XL, Zhang ZC, Zhang B, Jiang H, Yu CM, Zhang WJ, et al. Atorvastatin calcium in combination with methylprednisolone for the treatment of multiple sclerosis relapse. Int Immunopharmacol. 2014;23(2):546-9. [PubMed: 25448497].
  • 27. Ghasami K, Faraji F, Fazeli M, Ghazavi A, Mosayebi G. Interferon beta-1a and Atorvastatin in the Treatment of Multiple Sclerosis. Iran J Immunol. 2016;13(1):16-26. [PubMed: 27026043].
  • 28. Mroz RM, Lisowski P, Tycinska A, Bierla J, Trzeciak PZ, Minarowski L, et al. Anti-inflammatory effects of atorvastatin treatment in chronic obstructive pulmonary disease. A controlled pilot study. J Physiol Pharmacol. 2015;66(1):111-28. [PubMed: 25716971].
  • 29. Doan T, Melvold R, Viselli S, Valtenbaugh C. Immunology: Wolters Kluwer Health. 2012.
  • 30. Mak TW, Saunders ME, Jett BD. Primer to the Immune Response. Elsevier Science; 2013.
  • 31. Yu SF, Zhang YN, Yang BY, Wu CY. Human memory, but not naive, CD4+ T cells expressing transcription factor T-bet might drive rapid cytokine production. J Biol Chem. 2014;289(51):35561-9. doi: 10.1074/jbc.M114.608745. [PubMed: 25378399]. [PubMed Central: PMC4271239].
  • 32. Abbas AK, Lichtman AHH, Pillai S. Basic Immunology: Functions and Disorders of the Immune System. Elsevier Health Sciences; 2012.
  • 33. Yagi R, Zhu J, Paul WE. An updated view on transcription factor GATA3-mediated regulation of Th1 and Th2 cell differentiation. Int Immunol. 2011;23(7):415-20. doi: 10.1093/intimm/dxr029. [PubMed: 21632975]. [PubMed Central: PMC3123974].
  • 34. Aggarwal S, Gurney AL. IL-17: prototype member of an emerging cytokine family. J Leukoc Biol. 2002;71(1):1-8. [PubMed: 11781375].
  • 35. Ivanov ,I, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ, et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell. 2006;126(6):1121-33. doi: 10.1016/j.cell.2006.07.035. [PubMed: 16990136].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments